Original research: Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab (7 January, 2022)
Charles Miller, Hanson Kwok, Paul Harrow, Roser Vega, Edward Seward, Shameer Mehta, Farooq Rahman, Sara McCartney, Ioanna Parisi, Samuel Hsiang Lim, Esha Sharma, Mark A Samaan, Aaron Bancil, Klaartje Bel Kok, Ahmed Shalabi, Emma L Johnston, Dev Katarey, Nina Taherzadeh, Charles Murray, Mohammed Tauseef Sharip, Martyn J Carter, Shiva T Radhakrishnan, Simon Peake, Imran Khakoo, Mahmood Wahed, Sebastian Povlsen, Mehul Patel, Patrick DuBois, Jemima Finkel, Clive Onnie, Stuart Bloom
Commentary